When Lowering the Odds of Cancer Isn't Enough

CBSSM co-director Angela Fagerlin was quoted in an article in the New York Times by Tara Parker-Pope focusing on the use of tamoxifen and raloxifene to reduce the risk of cancer in women at risk for developing breast cancer.  Fagerlin discussed her research, which found that when the risks of tamoxifen were clearly described in an understandable, women were not interested in taking the medication.  She also discussed her research on the use of raloxifene, with similar findings.